An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults with Transthyretin Amyloid Cardiomyopathy - LTSAFE-ALXN

Study identifier:D6810C00002

ClinicalTrials.gov identifier:NCT07789483

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Medical condition

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Phase

Phase 3

Healthy volunteers

No

Study drug

ALXN2220

Sex

All

Estimated Enrollment

1180

Study type

Interventional

Age

N/A

Date

Study Start Date: 23 Nov 2027
Estimated Primary Completion Date: 11 Jul 2030
Estimated Study Completion Date: 11 Jul 2030

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2026 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria